Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

What Was Tested

Researchers studied Somatostatin and Lanreotide in this clinical trial, phase ii publication.

Somatostatin analogues (SSAs) are indicated to relieve carcinoid syndrome but seem to have antiproliferative effects on neuroendocrine tumours (NETs).

This is the first prospective study investigating tumour stabilisation with the long-acting SSA lanreotide Autogel in patients with progressive NETs.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a open-label and multicenter study.

Everyone knew when Somatostatin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

This was a multicentre, open-label, phase II trial conducted in 17 Spanish specialist centres.

The primary endpoint was progression-free survival (PFS).

Secondary endpoints were response rate, tumour biomarkers, symptom control, quality of life (QoL), and safety.

Radiographic imaging was assessed by a blinded central radiologist.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Cell Proliferation, Combined Modality Therapy, Disease Progression, Neoplasm Grading, Neuroendocrine Tumors and Peptides, Cyclic.

What This Means in Plain Language

The paper is an open-label and multicenter study of Somatostatin and Lanreotide.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (BMC cancer), a journal based in England.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.